Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer

PURPOSE: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor (AR) inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK) and activity of once-d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res Treat
Hlavní autoři: Bardia, Aditya, Gucalp, Ayca, DaCosta, Noashir, Gabrail, Nashat, Danso, Michael, Ali, Haythem, Blackwell, Kimberly L., Carey, Lisa A., Eisner, Joel R., Baskin-Bey, Edwina S., Traina, Tiffany A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6226357/
https://ncbi.nlm.nih.gov/pubmed/29744674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4813-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky